InvestSMART

Racura Oncology Ltd (ASX:RAC)

ALERT: Price-sensitive ASX Announcement for RAC
Current share price for RAC : $2.100 -0.18 (-7.89%)+
Announcement
Release
3 Jul 2026 8:46AM
Price at Release
$2.280
Full Release
download
Summary
Racura Oncology Ltd announced the Bellberry Human Research Ethics Committee (HREC) approval for the HARNESS-1 lung cancer trial, which permits the activation of additional clinical trial sites in Australia. The HARNESS-1 trial is a multi-centre Phase 1a/b study assessing the safety and efficacy of RC220 in combination with osimertinib in non-small cell lung cancer (NSCLC) patients. With this approval, significant Australian cancer care centers like Chris O’Brien Lifehouse and Austin Health will proceed with governance and start-up activities. The study involves the use of circulating tumour DNA (ctDNA) for patient screening and aims to identify optimal dosing for RC220. The trial is registered on the Australian and New Zealand clinical trial registry.
Key Points
  • Bellberry Human Research Ethics Committee (HREC) approved the HARNESS-1 lung cancer trial.
  • Approval enables additional clinical trial sites in Australia to participate in the HARNESS-1 study.
  • Chris O’Brien Lifehouse and Austin Health to start governance and start-up activities.
  • HARNESS-1 is a Phase 1a/b study evaluating RC220 with osimertinib in NSCLC patients.
  • The study uses circulating tumour DNA (ctDNA) for screening.
  • The trial is registered on the Australian and New Zealand clinical trial registry with code ACTRN12626000325303.
  • Racura Oncology is advancing RC220 across multiple oncology indications.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.